I reckon we will report the following stats for FY21 and FY22 as per below
- H1 FY21 NPAT $23M (NPAT to sales of 5%)
- H2 FY21 NPAT $5M (NPAT to sales of <1%)
- H1 FY22 NPAT $15M (NPAT to sales of 3.5%)
- H2 FY22 NPAT $20M (NPAT to sales of 5%)
You tell me the valuation of this business. That is a very pessimistic view, but somewhat realistic.
Inventory levels were too high at Dec20. Their refusal to disclose inventory levels this time is causing the rout. Well done management on your incompetence.
- Forums
- ASX - By Stock
- Ann: May 2021 Business Update
I reckon we will report the following stats for FY21 and FY22 as...
-
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KGN (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.50 |
Change
0.050(1.12%) |
Mkt cap ! $451.7M |
Open | High | Low | Value | Volume |
$4.46 | $4.58 | $4.41 | $2.002M | 443.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 4776 | $4.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.50 | 980 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 10484 | 4.480 |
16 | 15672 | 4.470 |
17 | 25588 | 4.460 |
11 | 8805 | 4.450 |
11 | 6640 | 4.440 |
Price($) | Vol. | No. |
---|---|---|
4.500 | 7823 | 24 |
4.510 | 14948 | 17 |
4.520 | 9749 | 13 |
4.530 | 24845 | 13 |
4.540 | 5891 | 10 |
Last trade - 14.41pm 15/07/2024 (20 minute delay) ? |
Featured News
KGN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online